Dmitry Skvortsov, Irina Zhirkina, Daria Ipatova, Lilya Vasilyeva, Yan Ivanenkov, Maria Rubtsova, Victor Kartsev, Petr Sergiev, Olga Dontsova
{"title":"Co-Culture Based Screening Revealed Selective Cytostatic Effects of Pyrazol-Azepinoindoles.","authors":"Dmitry Skvortsov, Irina Zhirkina, Daria Ipatova, Lilya Vasilyeva, Yan Ivanenkov, Maria Rubtsova, Victor Kartsev, Petr Sergiev, Olga Dontsova","doi":"10.1002/cmdc.202500052","DOIUrl":null,"url":null,"abstract":"<p><p>This work focuses on the search for new small molecules for anticancer therapy using the Fluorescent Cells Co-Cultivation Test (FCCT). This method allows the control of the specificity of the action of compounds from the earliest stages of drug development. For the FCCT, labelled MCF7' breast cancer cells and non-cancerous breast MCF10A cells were co-cultured. Screening of 2025 compounds in the above system and previously developed co-culture of A549' with VA-13 yielded 16 selectively cytotoxic molecules. The results were confirmed by MTT assay for 7 of these molecules. Few are known as potential antitumor agents: angelicin, coumarin, and colchicine derivatives. However, the structures of macrocycle 1, pyrazole-azepinoindole derivative 2, and complex heterocyclic derivative 3 were not described as anticancer compounds according to the PubChem and SciFinder databases. Structure-activity relationships were investigated for 2, and its derivatives. The indole with a caprolactam ring (tetrahydro-azepinoindolone core) together with the pyrazolyl at the 3-position are the key elements of the pharmacophore. The optimized pyrazole-azepinoindole derivative 23 showed SI=18 for HCT116 vs VA-13 on the expanded array of cell lines. I.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500052"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500052","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
This work focuses on the search for new small molecules for anticancer therapy using the Fluorescent Cells Co-Cultivation Test (FCCT). This method allows the control of the specificity of the action of compounds from the earliest stages of drug development. For the FCCT, labelled MCF7' breast cancer cells and non-cancerous breast MCF10A cells were co-cultured. Screening of 2025 compounds in the above system and previously developed co-culture of A549' with VA-13 yielded 16 selectively cytotoxic molecules. The results were confirmed by MTT assay for 7 of these molecules. Few are known as potential antitumor agents: angelicin, coumarin, and colchicine derivatives. However, the structures of macrocycle 1, pyrazole-azepinoindole derivative 2, and complex heterocyclic derivative 3 were not described as anticancer compounds according to the PubChem and SciFinder databases. Structure-activity relationships were investigated for 2, and its derivatives. The indole with a caprolactam ring (tetrahydro-azepinoindolone core) together with the pyrazolyl at the 3-position are the key elements of the pharmacophore. The optimized pyrazole-azepinoindole derivative 23 showed SI=18 for HCT116 vs VA-13 on the expanded array of cell lines. I.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.